<DOC>
	<DOC>NCT02416258</DOC>
	<brief_summary>The purpose of this study is to evaluate the anti-psoriatic effect of LP0113 aerosol spray compared to DaivobetÂ® gel, LEO 90100 aerosol foam, betamethasone dipropionate in the aerosol spray vehicle, calcipotriol in the aerosol spray vehicle and aerosol spray vehicle.</brief_summary>
	<brief_title>A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Connective Tissue Diseases</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<criteria>Signed and dated informed consent has been obtained Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs and/or trunk. The lesions must have a total size suitable for application of 6 different products. Age 18 years or above Outpatients Female subjects must be of either nonchildbearing potential, i.e. postmenopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus or has tubal ligation) or, childbearing potential provided there is a confirmed negative pregnancy test prior to trial treatment to rule out pregnancy. Female subjects who are breast feeding Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: Etanercept within 4 weeks prior to randomisation and during the trial Adalimumab, infliximab within 8 weeks prior to randomisation and during the trial Ustekinumab within 16 weeks prior to randomisation and during the trial Other products within 4 weeks/5 halflives prior to randomisation and during the trial (whichever is longer) Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within the 4week period prior to randomisation and during the trial, Subjects using phototherapy within the following time periods prior to randomisation and during the trial: PUVA: 4 weeks UVB: 2 weeks Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the trial: Potent or very potent (WHO group IIIIV) corticosteroids Subjects using one of the following topical drugs for the treatment of psoriasis within 2 weeks prior to randomisation and during the trial: WHO group III corticosteroids (except if used for treatment of scalp and/or facial psoriasis) Topical retinoids, Vitamin D analogues, Topical immunomodulators (e.g. calcineurin inhibitors), Tar products, Salicylic acid Subjects using emollients on the selected plaques within 1 week before randomisation and during the trial Initiation of, or expected changes to concomitant medication that may affect psoriasis vulgaris (e.g., beta blockers, antimalarial drugs, lithium and ACE inhibitors) within 2 weeks prior to the randomisation and during the trial Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>